Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma

Journal of Pathology

Volumn 220, Issue 3, 2010, Pages 392-400

  Madore, Jason ^a   Ren, Fengge ^a,b   Filali Mouhim, Ali ^a   Sanchez, Lilia ^a   Köbel, Martin ^c   Tonin, Patricia N ^d,e   Huntsman, David ^c   Provencher, Diane M ^a,f   Mes Masson, Anne Marie ^a,f  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b SHANXI MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^e MCGILL UNIVERSITY   (Canada)

^f UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

DNA microarray; Endometrioid carcinoma; Epithelial ovarian cancer; Histotype differential diagnosis; Immunohistochemistry; Serous carcinoma; Tissue microarray

Indexed keywords

BETA CATENIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; WT1 PROTEIN;

ARTICLE; CONTROLLED STUDY; DNA MICROARRAY; ENDOMETRIOID CARCINOMA; GENE EXPRESSION; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; OVARY CARCINOMA; OVARY ENDOMETRIOID CARCINOMA; OVARY SEROUS CARCINOMA; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TISSUE MICROARRAY;

EID: 75749089634     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2659     Document Type: Article

References (51)

1. Gilks CB. Subclassification of ovarian surface epithelial tumors based on correlation of histologic and molecular pathologic data. Int J Gynecol Pathol 2004;23(3):200-205.
2. Pieretti M, Hopenhayn-Rich C, Khattar NH, Cao Y, Huang B, Tucker TC. Heterogeneity of ovarian cancer: relationships among histological group, stage of disease, tumor markers, patient characteristics, and survival. Cancer Invest 2002;20(1):11-23.
3. Wang V, Li C, Lin M, Welch W, Bell D, Wong YF, et al. Ovarian cancer is a heterogeneous disease. Cancer Genet Cytogenet 2005;161(2):170-173.
4. Bell DA. Origins and molecular pathology of ovarian cancer. Mod Pathol 2005;18(suppl 2):S19-32.
5. Caduff RF, Svoboda-Newman SM, Ferguson AW, Johnston CM, Frank TS. Comparison of mutations of Ki-RAS and p53 immunoreactivity in borderline and malignant epithelial ovarian tumors. Am J Surg Pathol 1999;23(3):323-328.
6. Seidman JD, Kurman RJ. Pathology of ovarian carcinoma. Hematol Oncol Clin N Am 2003;17(4):909-925, vii.
7. Cramer SF, Roth LM, Ulbright TM, Mazur MT, Nunez CA, Gersell DJ, et al. Evaluation of the reproducibility of the World Health Organization classification of common ovarian cancers. With emphasis on methodology. Arch Pathol Lab Med 1987;111(9):819-829.
8. Gilks CB, Ionescu DN, Kalloger SE, Kobel M, Irving J, Clarke B, et al. Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma. Hum Pathol 2008;39(8):1239-1251.
9. Schwartz DR, Kardia SL, Shedden KA, Kuick R, Michailidis G, Taylor JM, et al. Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res 2002;62(16):4722-4729.
10. Hilton JL, Geisler JP, Rathe JA, Hattermann-Zogg MA, DeYoung B, Buller RE. Inactivation of BRCA1 and BRCA2 in ovarian cancer. J Natl Cancer Inst 2002;94(18):1396-1406.
11. Scully RE. Pathology of ovarian cancer precursors. J Cell Biochem Suppl 1995;23:208-218.
12. Piek JM, Kenemans P, Verheijen RH. Intraperitoneal serous adenocarcinoma: a critical appraisal of three hypotheses on its cause. Am J Obstet Gynecol 2004;191(3):718-732.
13. Medeiros F, Muto MG, Lee Y, Elvin JA, Callahan MJ, Feltmate C, et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol 2006;30(2):230-236.
14. Kindelberger DW, Lee Y, Miron A, Hirsch MS, Feltmate C, Medeiros F, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am J Surg Pathol 2007;31(2): 161-169.
15. Lee Y, Miron A, Drapkin R, Nucci MR, Medeiros F, Saleemuddin A, et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol 2007;211(1):26-35.
16. Bell KA, Kurman RJ. A clinicopathologic analysis of atypical proliferative (borderline) tumors and well-differentiated endometrioid adenocarcinomas of the ovary. Am J Surg Pathol 2000;24(11):1465- 1479.
17. Dinulescu DM, Ince TA, Quade BJ, Shafer SA, Crowley D, Jacks T. Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat Med 2005;11(1):63-70.
18. Shimizu M, Toki T, Takagi Y, Konishi I, Fujii S. Immunohistochemical detection of the Wilms' tumor gene (WT1) in epithelial ovarian tumors. Int J Gynecol Pathol 2000;19(2):158-163.
19. Acs G, Pasha T, Zhang PJ. WT1 is differentially expressed in serous, endometrioid, clear cell, and mucinous carcinomas of the peritoneum, fallopian tube, ovary, and endometrium. Int J Gynecol Pathol 2004;23(2):110- 118.
20. Waldstrom M, Grove A. Immunohistochemical expression of Wilms' tumor gene protein in different histologic subtypes of ovarian carcinomas. Arch Pathol Lab Med 2005;129(1):85-88.
21. Cathro HP, Stoler MH. The utility of calretinin, inhibin, and WT1 immunohistochemical staining in the differential diagnosis of ovarian tumors. Hum Pathol 2005;36(2):195-201.
22. Berchuck A, Kohler MF, Marks JR, Wiseman R, Boyd J, Bast RC Jr. The p53 tumor suppressor gene frequently is altered in gynecologic cancers. Am J Obstet Gynecol 1994;170(1, pt 1):246-252.
23. Buller RE, Lallas TA, Shahin MS, Sood AK, Hatterman-Zogg M, Anderson B, et al. The p53 mutational spectrum associated with BRCA1 mutant ovarian cancer. Clin Cancer Res 2001;7(4):831-838.
24. Palacios J, Gamallo C. Mutations in the β-catenin gene (CTNNB1) in endometrioid ovarian carcinomas. Cancer Res 1998;58(7):1344-1347.
25. Gamallo C, Palacios J, Moreno G, Calvo de Mora J, Suarez A, Armas A. β-Catenin expression pattern in stage I and II ovarian carcinomas : relationship with β-catenin gene mutations, clinicopathological features, and clinical outcome. Am J Pathol 1999;155(2):527-536.
26. Willner J, Wurz K, Allison KH, Galic V, Garcia RL, Goff BA, et al. Alternate molecular genetic pathways in ovarian carcinomas of common histological types. Hum Pathol 2007;38(4):607-613.
27. Obata K, Hoshiai H. Common genetic changes between endometriosis and ovarian cancer. Gynecol Obstet Invest 2000;50(suppl 1):39-43.
28. Kurose K, Zhou XP, Araki T, Cannistra SA, Maher ER, Eng C. Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas. Am J Pathol 2001;158(6):2097-2106.
29. Chang K, Ding I, Kern FG, Willingham MC. Immunohistochemical analysis of p53 and HER-2/neu proteins in human tumors. J Histochem Cytochem 1991;39(9):1281-1287.
30. Katabuchi H, Tashiro H, Cho KR, Kurman RJ, Hedrick Ellenson L. Micropapillary serous carcinoma of the ovary: an immunohistochemical and mutational analysis of p53 . Int J Gynecol Pathol 1998;17(1):54- 60.
31. Nenutil R, Smardova J, Pavlova S, Hanzelkova Z, Muller P, Fabian P, et al. Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry. J Pathol 2005;207(3):251-259.
32. Wu R, Hendrix-Lucas N, Kuick R, Zhai Y, Schwartz DR, Akyol A, et al. Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/β-catenin and PI3K/Pten signaling pathways. Cancer Cell 2007;11(4):321-333.
33. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 2004;5(10):R80.
34. Goldstein NS, Uzieblo A. WT1 immunoreactivity in uterine papillary serous carcinomas is different from ovarian serous carcinomas. Am J Clin Pathol 2002;117(4):541-545.
35. Sumathi VP, Al-Hussaini M, Connolly LE, Fullerton L, McCluggage WG. Endometrial stromal neoplasms are immunoreactive with WT-1 antibody. Int J Gynecol Pathol 2004;23(3):241-247.
36. Kobel M, Kalloger SE, Boyd N, McKinney S, Mehl E, Palmer C, et al. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med 2008;5(12):e232.
37. Barbolina MV, Adley BP, Shea LD, Stack MS. Wilms tumor gene protein 1 is associated with ovarian cancer metastasis and modulates cell invasion. Cancer 2008;112(7):1632-1641.
38. Hogdall EV, Christensen L, Kjaer SK, Blaakaer J, Christensen IJ, Gayther S, et al. Expression level of Wilms' tumor 1 (WT1) protein has limited prognostic value in epithelial ovarian cancer: from the Danish 'MALOVA' ovarian cancer study. Gynecol Oncol 2007;106(2):318-324.
39. Tonin PN, Hudson TJ, Rodier F, Bossolasco M, Lee PD, Novak J, et al. Microarray analysis of gene expression mirrors the biology of an ovarian cancer model. Oncogene 2001;20(45):6617-6626.
40. Wu R, Zhai Y, Fearon ER, Cho KR. Diverse mechanisms of β-catenin deregulation in ovarian endometrioid adenocarcinomas. Cancer Res 2001;61(22):8247-8255.
41. Manderson EN, Mes-Masson AM, Novak J, Lee PD, Provencher D, Hudson TJ, et al. Expression profiles of 290 ESTs mapped to chromosome 3 in human epithelial ovarian cancer cell lines using DNA expression oligonucleotide microarrays. Genome Res 2002;12(1):112-121.
42. Presneau N, Mes-Masson AM, Ge B, Provencher D, Hudson TJ, Tonin PN. Patterns of expression of chromosome 17 genes in primary cultures of normal ovarian surface epithelia and epithelial ovarian cancer cell lines. Oncogene 2003;22(10):1568-1579.
43. Samouelian V, Maugard CM, Jolicoeur M, Bertrand R, Arcand SL, Tonin PN, et al. Chemosensitivity and radiosensitivity profiles of four new human epithelial ovarian cancer cell lines exhibiting genetic alterations in BRCA2, TGFβ-RII, KRAS2, TP53 and/or CDNK2A. Cancer Chemother Pharmacol 2004;54(6):497-504.
44. Gagne JP, Gagne P, Hunter JM, Bonicalzi ME, Lemay JF, Kelly I, et al. Proteome profiling of human epithelial ovarian cancer cell line TOV-112D. Mol Cell Biochem 2005;275(1-2):25-55.
45. Smith JA, Ngo H, Martin MC, Wolf JK. An evaluation of cytotoxicity of the taxane and platinum agents combination treatment in a panel of human ovarian carcinoma cell lines. Gynecol Oncol 2005;98(1):141-145.
46. Popadiuk CM, Xiong J, Wells MG, Andrews PG, Dankwa K, Hirasawa K, et al. Antisense suppression of pygopus2 results in growth arrest of epithelial ovarian cancer. Clin Cancer Res 2006;12(7, pt 1):2216-2223.
47. Birch AH, Quinn MC, Filali-Mouhim A, Provencher DM, Mes-Masson AM, Tonin PN. Transcriptome analysis of serous ovarian cancers identifies differentially expressed chromosome 3 genes. Mol Carcinog 2007;47:56-65.
48. Zietarska M, Maugard CM, Filali-Mouhim A, Alam-Fahmy M, Tonin PN, Provencher DM, et al. Molecular description of a 3D in vitro model for the study of epithelial ovarian cancer (EOC). Mol Carcinog 2007;46(10):872-885.
49. McCabe A, Dolled-Filhart M, Camp RL, Rimm DL. Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis. J Natl Cancer Inst 2005;97(24):1808-1815.
50. Shih Ie M, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 2004;164(5):1511-1518.
51. Schmeler KM, Gershenson DM. Low-grade serous ovarian cancer: a unique disease. Curr Oncol Rep 2008;10(6):519-523.